LY3434172

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3434172, covering 2025-01-15 to 2025-01-15. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer [Phase 1]